| 纯度 | > 95 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | ANXA5 |
| Uniprot No | P08758 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-320aa |
| 氨基酸序列 | AQVLRGTVTDFPGFDERADAETLRKAMKGLGTDEESILTLLTSRSNAQRQEISAAFKTLFGRDLLDDLKSELTGKFEKLIVALMKPSRLYDAYELKHALKGAGTNEKVLTEIIASRTPEELRAIKQVYEEEYGSSLEDDVVGDTSGYYQRMLVVLLQANRDPDAGIDEAQVEQDAQALFQAGELKWGTDEEKFITIFGTRSVSHLRKVFDKYMTISGFQIEETIDRETSGNLEQLLLAVVKSIRSIPAYLAETLYYAMKGAGTDDHTLIRVMVSRSEIDLFNIRKEFRKNFATSLYSMIKGDTSGDYKKALLLLCGEDD |
| 预测分子量 | 37.8kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ANXA5重组蛋白的3篇代表性文献概览：
---
1. **文献名称**: *"High-yield production of recombinant human annexin A5 in Escherichia coli and its structural characterization"*
**作者**: Zhang Y. et al.
**摘要**: 该研究报道了通过大肠杆菌表达系统高效生产重组人ANXA5蛋白的方法，优化了纯化工艺并通过质谱和圆二色光谱验证其结构与天然蛋白的一致性，为大规模制备提供了技术基础。
2. **文献名称**: *"Annexin A5 inhibits endothelial cell inflammation by modulating the NF-κB signaling pathway"*
**作者**: Wang L. et al.
**摘要**: 研究揭示重组ANXA5蛋白通过结合细胞膜磷脂抑制NF-κB通路，减少炎症因子释放，提示其在治疗动脉粥样硬化等炎症性疾病中的潜在应用价值。
3. **文献名称**: *"Recombinant annexin A5 as a molecular imaging probe for detecting apoptosis in cancer therapy"*
**作者**: Brown J.E. et al.
**摘要**: 利用荧光标记的重组ANXA5蛋白特异性结合凋亡细胞表面的磷脂酰丝氨酸，成功实现肿瘤治疗过程中凋亡细胞的无创动态成像，为疗效评估提供新工具。
---
**注**：上述文献信息为模拟示例，实际引用时需通过PubMed或Web of Science等数据库核对原文信息。如需具体文献，建议以关键词“recombinant annexin A5”结合研究领域(如“expression”、“anticoagulant”、“apoptosis imaging”)进行检索。
Annexin A5 (ANXA5), a member of the annexin superfamily, is a calcium-dependent phospholipid-binding protein widely recognized for its affinity to phosphatidylserine (PS). This 35-36 kDa protein plays a key role in membrane-related processes, including apoptosis, coagulation, and inflammation. Naturally expressed in various tissues, ANXA5 stabilizes membrane integrity by forming ordered 2D arrays on PS-exposing surfaces, a feature critical for its function in inhibiting blood coagulation and marking apoptotic cells for phagocytosis.
Recombinant ANXA5 is produced via genetic engineering, typically expressed in *E. coli* or mammalian systems, followed by purification using chromatographic techniques. Its recombinant form retains the conserved core domain structure, enabling calcium-mediated binding to PS while excluding the variable N-terminal region, which may differ across species. This modification enhances consistency for research and diagnostic applications.
In biomedical research, recombinant ANXA5 is widely employed as a probe in apoptosis detection assays (e.g., Annexin V-FITC/PI staining) to distinguish early apoptotic cells. It also serves as a tool to study thrombosis mechanisms due to its anticoagulant properties. Clinically, it underpins diagnostic kits for detecting anti-phospholipid antibodies in autoimmune disorders like antiphospholipid syndrome. Recent studies explore its potential in targeted drug delivery and imaging, leveraging its PS-binding specificity in pathological tissues such as tumors or atherosclerotic plaques.
The protein’s stability, specificity, and non-immunogenic nature make it indispensable in both basic science and translational medicine. Ongoing research continues to expand its therapeutic applications, particularly in diseases involving aberrant PS exposure.
×
